Vogenx Inc Common Stock (VOGX) - Net Assets
Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has net assets worth $-1.40 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($898.46K) and total liabilities ($2.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Vogenx Inc Common Stock (VOGX) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.40 Million |
| % of Total Assets | -155.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Vogenx Inc Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Vogenx Inc Common Stock (VOGX) market capitalisation.
Annual Net Assets for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual net assets of Vogenx Inc Common Stock from 2024 to 2025. Also explore net asset momentum of Vogenx Inc Common Stock to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-919.24K | -280.39% |
| 2024-12-31 | $509.58K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vogenx Inc Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 144560300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.92 Million | % |
| Total Equity | $-919.24K | 100.00% |
Vogenx Inc Common Stock Competitors by Market Cap
The table below lists competitors of Vogenx Inc Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aduro Clean Technologies Inc. Common Stock
NASDAQ:ADUR
|
$442.69 Million |
|
Linc AB
ST:LINC
|
$442.73 Million |
|
Pitti Engineering Limited
NSE:PITTIENG
|
$442.84 Million |
|
Oxford Industries Inc
NYSE:OXM
|
$442.85 Million |
|
Beijing Succeeder Technology Inc
SHG:688338
|
$442.66 Million |
|
Joyware Electronics Co Ltd
SHE:300270
|
$442.66 Million |
|
Jay Mart Public Company Limited
BK:JMART
|
$442.62 Million |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
$442.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vogenx Inc Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 509,584 to -919,235, a change of -1,428,819 (-280.4%).
- Net loss of 1,445,603 reduced equity.
- Other factors increased equity by 16,784.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.45 Million | -157.26% |
| Other Changes | $16.78K | +1.83% |
| Total Change | $- | -280.39% |
Book Value vs Market Value Analysis
This analysis compares Vogenx Inc Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.04 | $32.21 | x |
| 2025-12-31 | $-0.07 | $32.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vogenx Inc Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-216.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -432.43% | 0.00% | 0.00x | 1.90x | $-2.25 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
Industry Comparison
This section compares Vogenx Inc Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vogenx Inc Common Stock (VOGX) | $-1.40 Million | -432.43% | N/A | $442.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more